HOME > TOP STORIES

TOP STORIES

ORGANIZATION JMA’s Nakagawa Pushes Price Cuts Even on Non-100 Billion Yen Products, Eyes Other Hep C Drugs

January 18, 2017
REGULATORY Counterfeit Harvoni Discovered in Nara Pharmacy, MHLW Investigating Route of Entry into Distribution

January 18, 2017
REGULATORY MHLW to Ponder Additional Gap-Year Price Survey Method That Won’t Cripple Single-Product, Single-Price Efforts: Kanda

January 17, 2017
INTERVIEW MHLW’s Sakoi Calls on Industry to Transcend Corporate Boundaries, Join Pricing Reform Debate

January 16, 2017
REGULATORY PMDA Stops Increasing Review Staff, Current Review-Time Targets to Remain Unchanged: Chief Executive

January 16, 2017
REGULATORY Industry Speculating Tax Hike Will Delay Annual Revision Rollout to 2021

January 13, 2017
REGULATORY Chuikyo Industry, Doctor Reps in Discord over Scope of Price Review for Indication Expansions

January 12, 2017
BUSINESS Ariad Deal Is “Global Acquisition” Not Limited to US Market: Takeda CEO

January 11, 2017
REGULATORY Chuikyo to Kick Off Debates to Elaborate Pricing Revamp; 2 Industry Hearing Sessions Planned

January 11, 2017
BUSINESS Opdivo Gastric Cancer Filing Casts Cloud on Keytruda’s Sakigake Status

January 10, 2017
BUSINESS Takeda to Buy US Oncology Firm Ariad

January 10, 2017
REGULATORY MHLW to Regularly Compile Optimal Drug Use Guidelines from FY2017: Pharma Bureau Chief

January 6, 2017
REGULATORY From Regulatory Agency to Industry-Fostering Agency: Health Minister

January 5, 2017
REGULATORY Policymakers Rolling Up Their Sleeves to Embody Drug Pricing Overhaul

January 1, 2017
REGULATORY AMED Plans to Introduce Medical-Economic Viewpoints for Its R&D Support

December 28, 2016
BUSINESS 40 Billion Yen Sales for Oncology Business in FY2020 Achievable: Daiichi Sankyo

December 27, 2016
ORGANIZATION Novo’s Ole Moelskov Bech to Helm EFPIA Japan from January

December 26, 2016
BUSINESS Sumitomo Dainippon to Buy US Hematology Startup Tolero

December 22, 2016
BUSINESS Ono Slashes Opdivo Sales Outlook on 50% Price Cut

December 22, 2016
REGULATORY Quarterly Price Reviews for Indication-Added Drugs Likely to Get Underway in FY2017, Annual Scheme in FY2018: Officials

December 21, 2016

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…